Catalysts
ABSI Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
ABSIAbsci Corporation
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum85
- Value—
- Quality26
- Risk resilience30
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
No upcoming reporting date is available yet.
Momentum 85/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 13.71%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | — | -$0.19 | -$0.19 | -0.6% | $657.81K | $304K |
| Aug 11, 2026 | — | -$0.19 | -$0.18 | +5.8% | $919.58K | $300K |
| May 7, 2026 | — | -$0.20 | -$0.19 | +5.0% | $1.26M | $215K |
| Mar 24, 2026 | — | -$0.16 | -$0.23 | -43.8% | $1.34M | $650K |
| Nov 12, 2025 | — | -$0.19 | -$0.20 | -5.3% | $1.38M | $378K |
| Aug 12, 2025 | — | -$0.19 | -$0.24 | -26.3% | $5.17M | $593K |
| May 13, 2025 | — | -$0.23 | -$0.21 | +8.7% | $1.3M | $1.18M |
| Mar 18, 2025 | — | -$0.22 | -$0.25 | -13.6% | $4.87M | $665K |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Upcoming earnings date not available yet.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Absci Names Gerry Muhle Chief Commercial Officer, Shares Down In Pre-market
Thursday, Absci Corp. (ABSI), a clinical pharmaceutical company, appointed Gerry Muhle as Chief Commercial Officer to lead its commercial strategy and support the development and commercialization of ABS-201 and its broader drug pipeline.
Related Links
ABSI Catalysts FAQ
What are the next catalysts for ABSI stock?
ABSI's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move ABSI stock?
Upcoming events that could move ABSI include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could ABSI's next earnings report affect the stock?
ABSI's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive ABSI stock higher?
ABSI could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt ABSI stock?
ABSI could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.